Topical Bevacizumab 0.05% Eye Drops for Preventing Recurrent Pterygium, A Randomized, Double-masked, Controlled Trial
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Pterygium
- Focus Therapeutic Use
- 05 Oct 2015 New trial record
- 23 Sep 2015 Results published in the Clinical Therapeutics.
- 23 Sep 2015 Status changed from recruiting to completed as per results published in the Clinical Therapeutics.